Study of the Immunogenicity of the MUC1 Peptide - Poly-ICLC (Polyinosinic-polycytidylic Acid Stabilized With Polylysine and Carboxymethylcellulose) OR HILTONOL™ Adjuvant Vaccine in Patients With Localized and Locally Advanced Non-Small Cell Lung Cancer

Inclusion Criteria:

- Subjects must have histologically or cytologically confirmed non-small cell lung
cancer (NSCLC)

- All subjects must have one of the following stages: Stage IA(T1NO); IB (T2NO), II &
IIIA (N2 negative); IIIA (N2+), IIIB (N3+)

- Patients must have stable disease at the time of enrollment

- Women and men at least 18 years of age

- ECOG performance status 0-1(Appendix A)

- Subjects must be within 4 to 6 weeks of standard of care treatment for their
particular stage of disease

- Subjects must have acceptable organ and marrow function as defined below:

- Leukocytes > 3,000/µL

- Absolute Neutrophils > 1,500/µL

- Hemoglobin > 10 g/dL

- Platelets > 100,000/µL

- Total Bilirubin within normal institutional limits

- Creatinine within normal institutional limits OR

- Creatinine clearance > 60 mL/min/1.73 m2 for subjects with above normal AST and
ALT with alkaline phosphatase within < 1.5 times upper limit of normal

- The effects of a MUC1vaccine on the developing human fetus at the recommended
therapeutic dose are unknown. For this reason, men and women of childbearing
potential must be willing to use effective contraception (hormonal barrier method of
birth control; abstinence) while on study treatment and for at least 3 months
thereafter. Should a woman become pregnant or suspect she is pregnant while
participating in this study, she should inform her treating physician immediately

Exclusion Criteria:

- Subjects may not be receiving any other investigational agents

- Positive ANA lab result

- No prior vaccine therapy

- Patients may not be receiving any steroids or other anti-immune therapy at the time
of registration.

- Subjects must not be more than 6 weeks from standard of care treatment for their
particular stage of disease

- Subjects must not have post-obstructive pneumonia or other serious infection at the
time of registration or other serious underlying medical condition that would impair
the ability of the subjects to receive protocol treatment

- Prior resection of lung cancer is allowed, if at least five years have elapsed
between previous resection and registration

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements

- Pregnant women are excluded from this study. Women of childbearing potential must
have a negative pregnancy test

- Subjects with immune deficiency are not expected to respond to the vaccine.
Therefore, known HIV-positive patients are excluded from the study

- Subjects with a history of known autoimmune disease are excluded from this study